TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06259630
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant receives oral dose of placebo
Study: NCT02057406
Drug: 2:1 EPA/DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
Study: NCT01627431
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg once per day
Study: NCT03277248
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03277248
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an IV Infusion.
Study: NCT03720548
Drug: LY3372993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00302471
Drug: Comparator: MK0429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease.
Study: NCT00302471
Drug: Comparator: MK0429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study: NCT00302471
Drug: Comparator: MK0429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study: NCT00302471
Drug: Comparator: MK0429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study: NCT03720548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00931398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for all Concerta doses.
Study: NCT01200186
Drug: EV/DNG (Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the discretion of the attending physician
Study: NCT01200186
Drug: Progestin Only Pills
Normalized name: Prostin E2 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the discretion of the attending physician
Study: NCT04184947
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
Study: NCT01167335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00756860
Drug: Renagel® (sevelamer hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
Study: NCT02589067
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
Study: NCT01574027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule per day for six months
Study: NCT01514929
Drug: ACHN-490 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg IV 30 minute infusion given once
Study: NCT01472887
Drug: SAR3419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous
Study: NCT01514929
Drug: ACHN-490 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg IV 30 minute infusion given once
Study: NCT01514929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral pill given once
Study: NCT01426854
Drug: Nepafenac Ophthalmic Suspension, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular administration
Study: NCT02610647
Drug: Wrist anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
Study: NCT03929016
Drug: DNDI-0690
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules of 10, 100 and 200 mg
Study: NCT03929016
Drug: Placebo of DNDI-0690
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules of matching placebo
Study: NCT01710696
Drug: 17-beta estradiol
Normalized name: 17-beta estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
Study: NCT00757419
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, single or twice daily dose
Study: NCT00757419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match dosing of AZD3355
Study: NCT00950300
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study: NCT01656434
Drug: NOMAC-E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
Study: NCT04315896
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT04128540
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
Study: NCT01604239
Drug: Shinbaro Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg twice a day (b.i.d) oral herbal medicine
Study: NCT01693809
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02692716
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral use once daily.
Study: NCT04039815
Drug: Ascorbic acid-Vitamin B1-Hydrocortisone
Normalized name: ascorbic acid / vitamin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
Study: NCT04039815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Study: NCT03074591
Drug: Ferric Carboxymaltose 50Mg/Ml Inj 15Ml
Normalized name: FERRIC CARBOXYMALTOSE 50MG/ML INJ 15ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
Study: NCT03074591
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
Study: NCT01948622
Drug: Mulungu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/single dose/1 hour before dental surgery
Study: NCT01948622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/single dose/1 hour before dental surgery
Study: NCT02131220
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracoronary bolus infusion using selective catheter during PCI
Study: NCT03521934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01490190
Drug: Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)
Normalized name: ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
Study: NCT00337493
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled
Study: NCT00337493
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g po bid
Study: NCT02455232
Drug: 4cc of lidocaïne®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04107194
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT04107194
Drug: Tetracycline 125 MG
Normalized name: tetracycline 125 MG
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT00483743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 caps BID x42 days
Study: NCT00301886
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01257984
Drug: BAY86-5300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
Study: NCT01257984
Drug: BAY86-5300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
Study: NCT00516295
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04378608
Drug: OBV/PTV/r) ± ribavirin (RBV)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04459754
Drug: Fuzheng Yiliu Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption.
Study: NCT01218204
Drug: GSK1292263 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01218204
Drug: 100mg GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg
Study: NCT01218204
Drug: 300mg GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg
Study: NCT01218204
Drug: 800mg GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg
Study: NCT01139216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
Study: NCT03999008
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple Sauce 5 mL+ 1 mL saline
Study: NCT02532855
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
Study: NCT02285491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
Study: NCT03044873
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
Study: NCT02668367
Drug: BTA-C585 oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTA-C585; Multiple ascending doses from 100 mg to 600 mg
Study: NCT01811160
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A capsule of melatonin was administered nightly (20:00hrs).
Study: NCT01811160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were administered at 20:00hrs for eight weeks
Study: NCT00004162
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02751424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
Study: NCT03206749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to VX-150 and HB/APAP for 2 days.
Study: NCT01884844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081897
Drug: SPRANC Control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
Study: NCT03170739
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine given during surgery.
Study: NCT03820258
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily with food.
Study: NCT02542462
Drug: Rotarix®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of licensed rotavirus vaccine given alone
Study: NCT02542462
Drug: Rotarix®, with other routine vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Study: NCT02542462
Drug: RotaTeq®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of licensed rotavirus vaccine given alone
Study: NCT02542462
Drug: RotaTeq®, with other routine vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Study: NCT01676285
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01690780
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
Study: NCT05983289
Drug: HSK7653
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
Study: NCT05983289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
Study: NCT02082678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient matching the active medication in appearance
Study: NCT01531790
Drug: Centrum
Normalized name: Centrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/day
Study: NCT02784262
Drug: botox injection Multiguide
Normalized name: onabotulinumtoxinA Injection [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: botox injection under CT/MR navigation and with the navigation tool MultiGuide
Study: NCT03090113
Drug: Shuxuetong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous drip
Study: NCT03090113
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous drip
Study: NCT00001830
Drug: Th2 cells in allo HSCTT
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001830
Drug: Th2 Cells
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02349178
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
Study: NCT01572662
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Study: NCT03396380
Drug: Vitamin D with calcium and clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days .
Study: NCT03396380
Drug: Placebo Oral Tablet with calcium and clomiphene citrate
Normalized name: clomiphene Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days
Study: NCT00210639
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
Study: NCT03508921
Drug: Periprocedural Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection.
Study: NCT03508921
Drug: Extended Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only.
Study: NCT03520972
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 eligible patients will be included in this group
Study: NCT01860638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
Study: NCT03899454
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Control
Study: NCT01860638
Drug: SOC Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
Study: NCT01756885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
Study: NCT00182260
Drug: Proton Pump Inhibitors
Normalized name: Proton pump inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00897676
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (0.9% NaCl)
Study: NCT02946424
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 month course of daily placebo
Study: NCT02946424
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 month course of daily simvastatin
Study: NCT02317562
Drug: I10E
Normalized name: SET,INFUSION ACCU-CHEK ULTRAFLEX-I10-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
Study: NCT03551743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04502589
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disulfiram will be kept at 250mg daily
Study: NCT01522846
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
Study: NCT01936103
Drug: standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard statin treatment:Atorvastatin statins 20mg / night .
Study: NCT01936103
Drug: intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
Study: NCT03917914
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: As in arm description
Study: NCT01009476
Drug: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
Normalized name: Other psychostimulants and nootropics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
Study: NCT00577655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HFA MDI four times a day (q.i.d) for 21 days.
Study: NCT00577655
Drug: Proventil® HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.